Citadel Advisors
CURX

Citadel Advisors’s Curanex Pharmaceuticals CURX Stock Holding History

Citadel Advisors’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3K Buy
4,763
+2,235
+88% +$16.3K ﹤0.01% 13348
2026
Q1 		$25.9K Sell
2,528
-2,686
-52% -$20.2K ﹤0.01% 12618
2025
Q4 		$34.5K Buy
5,214
+2,011
+63% +$22.1K ﹤0.01% 12175
2025
Q3 		$46.1K Buy
+3,203
New +$290K ﹤0.01% 12244

Other funds holding CURX

VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citadel Advisors's CURX Position: Q2 2026 in Review

Citadel Advisors increased its Curanex Pharmaceuticals (CURX) stake by 88% in Q2 2026, buying an estimated $16.3K and bringing the position to 4,763 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #13348.

Citadel Advisors first reported a position in CURX in Q3 2025 and has held it in 4 quarters since. The position peaked at $46.1K in Q3 2025. 11 funds tracked by Wall St. Rank hold CURX as of Q2 2026.

  • Citadel Advisors held 4,763 shares of Curanex Pharmaceuticals worth $25.3K as of Q2 2026.
  • Citadel Advisors bought 2,235 Curanex Pharmaceuticals shares in Q2 2026, an estimated $16.3K.
  • Curanex Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13348 holding.
  • Citadel Advisors first reported a position in Curanex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Citadel Advisors's Curanex Pharmaceuticals position peaked at $46.1K in Q3 2025.
  • 11 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.